(Total Views: 436)
Posted On: 08/13/2021 11:26:54 AM
Post# of 154001
Sean,
I agree completely. Brazil has suffered immensely and further delays in finding solutions are unwarranted.
That being said, I believe there have been changes in the critical trial endpoints to better capture the degree and duration of clinical improvement, moving further from the binary dead/alive CD12 endpoint.
I have no explanation for the moderate trial not dosing after Biomm announcement August 2 of ANVISA approval.
Perhaps we can chalk it up to the euphemistic and nebulous "logistics".
I agree completely. Brazil has suffered immensely and further delays in finding solutions are unwarranted.
That being said, I believe there have been changes in the critical trial endpoints to better capture the degree and duration of clinical improvement, moving further from the binary dead/alive CD12 endpoint.
I have no explanation for the moderate trial not dosing after Biomm announcement August 2 of ANVISA approval.
Perhaps we can chalk it up to the euphemistic and nebulous "logistics".
(1)
(0)
